January 24, 2017
Probi praises Nutraceutix purchase, announces good Q4 results
Probi, Swedish bioengineering company that develops probiotics has reported Q4 2016 financial results.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
January 24, 2017
Horizon Discovery expects 2016 revenue up 20%
Horizon Discovery Group expects to see 2016 revenues rise for about 20%, as it expects revenue of at least £24.0 million.
January 24, 2017
Quantum Pharma grantes options to its CFO
Quantum Pharma, has granted options over 1,100,000 Ordinary Shares of 10 pence each (‘Ordinary Shares’) with an exercise price of 30 pence, to Gerard Murray, Chief Financial Officer.
January 24, 2017
Nicox to test new eye drug
Nicox, the international ophthalmic R&D company, has provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide…
January 24, 2017
Exclusive: Canada seeks warnings on prescription painkillers amid rising deaths
As deaths from powerful painkillers continue to rise, Canada is pursuing unprecedented measures to curb their use, including requiring cigarette-style warning stickers on every prescription, Health Minister Jane Philpott told Reuters.
January 24, 2017
Asit’s Phase II study of dust allergy treatment shows success
Asit biotech has completed Phase IIa double-blind placebo-controlled clinical study in house dust mite-induced rhinoconjunctivitis.
January 24, 2017
Abzena to issue ordinary shares
Abzena has made application to the London Stock Exchange for the admission of 715,772 new ordinary shares of £0.002 each (‘New Ordinary Shares’) to trading on AIM.
January 24, 2017
Short: Van Herk Investments announces 10.07% Shareholding in Ablynx
Van Herk Investments B.V. has become owner of more than 10% of Ablynx as it has crossed the 10% threshold and now…
January 24, 2017
Vectura starts with testing asthma drug/device combination for children
Vectura Group is moving on with researching and testing its VR647, a drug/device combination to treat asthma in children for the US market.
January 24, 2017
Advanced Oncotherapy to take “appropriate action” against Sinophi Healthcare
Advanced Oncotherapy said on Tuesday it will “appropriately” deal with a UK company Sinophi Healthcare, which invests in and manages hospitals in China, because it wanted to drop purchase orders made two years ago.